GSK2606414: A Selective PERK Inhibitor for Precise ER Stress Research

Executive Summary: GSK2606414 is a potent and selective small molecule inhibitor of PERK (protein kinase R-like endoplasmic reticulum kinase), exhibiting an IC₅₀ of 0.4 nM in enzyme assays and complete inhibition of PERK phosphorylation at 30 nM in A549 cells (APExBIO product page). The compound demonstrates high selectivity, inhibiting only 20 of 294 kinases by more than 85% at 10 μM (Patra et al., 2020). GSK2606414 is orally bioavailable, with dose-dependent tumor growth inhibition in BxPC3 xenograft mice. It is widely used in research on ER stress, unfolded protein response modulation, and disease models in cancer and neurodegeneration (GSK3B.com). APExBIO supplies GSK2606414 as a solid for laboratory use, with recommended storage at -20°C.

Biological Rationale

Cells employ an integrated stress response to counteract disruptions in proteostasis, such as those caused by misfolded proteins in the endoplasmic reticulum (ER) (Patra et al., 2020). PERK (EIF2AK3) is a type I ER membrane protein that senses ER stress and attenuates global protein synthesis via phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2α). This pathway is central to the unfolded protein response (UPR), coordinating translational arrest and transcriptional programs to restore ER homeostasis. Dysregulation of PERK signaling is implicated in cancer, neurodegeneration, and metabolic disease. Pharmacological PERK inhibition enables precise dissection of UPR biology and the development of novel therapeutic strategies (MAP Kinase Fragment).

Mechanism of Action of GSK2606414

GSK2606414 is a small molecule that directly binds the kinase domain of PERK, as confirmed by X-ray crystallography (APExBIO). Upon ER stress, PERK autophosphorylates and phosphorylates eIF2α at serine 51, leading to global translational repression. GSK2606414 inhibits PERK activity with an IC₅₀ of 0.4 nM, preventing both autophosphorylation and downstream eIF2α phosphorylation. In cellular models, complete inhibition of PERK and eIF2α phosphorylation is achieved at 30 nM in A549 cells. The compound does not significantly inhibit the other three eIF2α kinases (GCN2, HRI, or PKR) at similar concentrations (Phosphatase Inhibitor), underscoring its selectivity for PERK.

Evidence & Benchmarks

• GSK2606414 inhibits PERK kinase activity with an IC₅₀ of 0.4 nM in biochemical assays (APExBIO).
• In A549 cell lines, 30 nM GSK2606414 completely inhibits PERK phosphorylation and downstream eIF2α phosphorylation under ER stress conditions (Patra et al., 2020).
• Compound demonstrates high selectivity, inhibiting only 20 of 294 kinases by >85% at 10 μM, while having negligible activity against GCN2, HRI, and PKR (APExBIO).
• GSK2606414 shows oral bioavailability and dose-dependent tumor growth inhibition in BxPC3 xenograft mouse models (APExBIO).
• Solubility: ≥22.57 mg/mL in DMSO, ≥12.03 mg/mL in ethanol (with gentle warming and ultrasound), insoluble in water (APExBIO).

This article builds on previous guidance by providing updated selectivity and workflow parameters, and extends advanced mechanistic insights on PERK inhibition in translational disease models.

Applications, Limits & Misconceptions

GSK2606414 is widely used in basic and translational research targeting the PERK signaling pathway in contexts such as cancer, neurodegenerative disorders (e.g., prion disease, Alzheimer's), and metabolic diseases. Inhibition of PERK enables researchers to dissect the unfolded protein response and its crosstalk with pathways like the Nrf2 antioxidant response (Patra et al., 2020).

Common Pitfalls or Misconceptions

• GSK2606414 is not water-soluble; attempts to dissolve in aqueous buffers typically fail. Use DMSO or ethanol with proper technique (APExBIO).
• The compound is selective for PERK but may inhibit a few off-target kinases at high micromolar concentrations; always validate selectivity in specific assay contexts.
• Long-term storage of GSK2606414 solutions is not recommended due to potential degradation; prepare fresh solutions for each experiment (APExBIO).
• PERK inhibition may not mimic genetic knockout due to adaptive cellular responses; interpret results with appropriate controls (MAP Kinase Fragment).
• Not all ER stress models are sensitive to PERK inhibition; other UPR arms (ATF6, IRE1) may compensate.

Workflow Integration & Parameters

For in vitro studies, GSK2606414 is typically dissolved in DMSO (≥22.57 mg/mL) and diluted to working concentrations (10–100 nM) in cell culture media. For in vivo models, oral administration is feasible due to high bioavailability, with reported efficacy in rodent xenograft tumor models. Solutions should be prepared fresh and used promptly. Storage as a solid at -20°C is recommended (APExBIO). APExBIO provides detailed handling protocols and troubleshooting tips for optimal experimental use. This article clarifies recent updates in benchmark concentrations and handling, extending earlier workflow-focused guidance (Phosphatase Inhibitor).

Conclusion & Outlook

GSK2606414 (A3448, APExBIO) is a benchmark selective PERK inhibitor for ER stress and unfolded protein response research. Its nanomolar potency, outstanding selectivity, and proven efficacy in both cellular and animal models have established it as a standard tool in cancer biology, neurodegeneration, and metabolic disease studies. Continued use and development of GSK2606414 will advance mechanistic understanding of ER stress responses and facilitate the translation of UPR-targeted therapies (Patra et al., 2020).